Cargando…

Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders

Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotfi, Abeya A, Mohamed, Asmaa E, Shalaby, Nahela A, Eissa, Deena S, El-Dabaa, Ehab, Sallam, Ayman M, Kamel, Mahmoud M, Abdelaziz, Hisham, El-Afifi, Amal M, Abdel-Moneim, Ahmed S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557643/
https://www.ncbi.nlm.nih.gov/pubmed/33045856
http://dx.doi.org/10.1177/2058738420961202
Descripción
Sumario:Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection.